Horizon Pharma plc Announces Exceptional Third-Quarter 2015 Financial Results and Significantly Raises Full-Year 2015 Sales and Adjusted EBITDA Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/13/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. MSFT
9. CRM
10. TGT

Go back to Horizon Pharma plc Announces Exceptional Third-Quarter 2015 Financial Results and Significantly Raises Full-Year 2015 Sales and Adjusted EBITDA Guidance

Guggenheim Shows Increasing Confidence in Horizon Pharma (HZNP) Following 3Q Beat; Reiterates Buy

November 6, 2015 11:10 AM EST

Guggenheim reiterated a Buy rating and $40.00 price target on Horizon Pharma (NASDAQ: HZNP) following the company's 3Q15 earnings report. HZNP reported adjusted diluted 3Q15 EPS of $0.70, $0.29 above consensus. The company also raised its '15 EBITDA guidance to $350MM-$360MM from $265MM-$280MM, consensus was... More

Horizon Pharma (HZNP) Tops Q3 EPS by 30c; Boosts FY15 Revenue Outlook

November 6, 2015 7:01 AM EST

Horizon Pharma (NASDAQ: HZNP) reported Q3 EPS of $0.70, $0.30 better than the analyst estimate of $0.40. Revenue for the quarter came in at $292.7 million versus the consensus estimate of $185.7 million.

Horizon Pharma sees FY2015 revenue of $750-760 million, versus prior guidance of $660-680 million and the... More